Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery.

Published on Mar 25, 2019in ACS Nano14.588
· DOI :10.1021/ACSNANO.8B07858
Jonas Buck3
Estimated H-index: 3
(University of Basel),
Philip Grossen8
Estimated H-index: 8
(University of Basel)
+ 2 AuthorsDominik Witzigmann16
Estimated H-index: 16
(University of Basel)
Gene therapy is a promising strategy for the treatment of monogenic disorders. Non-viral gene delivery systems including lipid-based DNA therapeutics offer the opportunity to deliver an encoding gene sequence specifically to the target tissue and thus enable the expression of therapeutic proteins in diseased cells. Currently, available gene delivery approaches based on DNA are inefficient and require improvements to achieve clinical utility. In this Review, we discuss state-of-the-art lipid-based DNA delivery systems that have been investigated in a preclinical setting. We emphasize factors influencing the delivery and subsequent gene expression in vitro, ex vivo, and in vivo. In addition, we cover aspects of nanoparticle engineering and optimization for DNA therapeutics. Finally, we highlight achievements of lipid-based DNA therapies in clinical trials.
📖 Papers frequently viewed together
44 Citations
3 Authors (Yang Liu, ..., Chen Jiang)
6 Citations
70 Citations
#1Sandro Sieber (University of Basel)H-Index: 9
#2Philip Grossen (University of Basel)H-Index: 8
Last. Jörg Huwyler (University of Basel)H-Index: 49
view all 7 authors...
Abstract Macrophage recognition of nanoparticles is highly influenced by particle size and surface modification. Due to the lack of appropriate in vivo screening models, it is still challenging and time-consuming to characterize and optimize nanomedicines regarding this undesired clearance mechanism. Therefore, we validate zebrafish embryos as an emerging vertebrate screening tool to assess the macrophage sequestration of surface modified particulate formulations with varying particle size under...
21 CitationsSource
#1Khalid A. Hajj (CMU: Carnegie Mellon University)H-Index: 4
#2Rebecca L. Ball (CMU: Carnegie Mellon University)H-Index: 8
Last. Kathryn A. Whitehead (CMU: Carnegie Mellon University)H-Index: 25
view all 7 authors...
: The potential of mRNA therapeutics will be realized only once safe and effective delivery systems are established. Unfortunately, delivery vehicle development is stymied by an inadequate understanding of how the molecular properties of a vehicle confer efficacy. Here, a small library of lipidoid materials is used to elucidate structure-function relationships and identify a previously unappreciated parameter-lipid nanoparticle surface ionization-that correlates with mRNA delivery efficacy. The ...
40 CitationsSource
#1Sandro Sieber (University of Basel)H-Index: 9
#2Philip Grossen (University of Basel)H-Index: 8
Last. Jörg Huwyler (University of Basel)H-Index: 49
view all 7 authors...
Abstract The interactions of nanomedicines with biological environments is heavily influenced by their physicochemical properties. Formulation design and optimization are therefore key steps towards successful nanomedicine development. Unfortunately, detailed assessment of nanomedicine formulations, at a macromolecular level, in rodents is severely limited by the restricted imaging possibilities within these animals. Moreover, rodent in vivo studies are time consuming and expensive, limiting the...
38 CitationsSource
#1Cory D. Sago (Georgia Institute of Technology)H-Index: 10
#2Melissa P. Lokugamage (Georgia Institute of Technology)H-Index: 8
Last. James E. Dahlman (Georgia Institute of Technology)H-Index: 24
view all 6 authors...
Bone marrow endothelial cells (BMECs) regulate their microenvironment, which includes hematopoietic stem cells. This makes BMECs an important target cell type for siRNA or gene editing (e.g., CRISPR) therapies. However, siRNA and sgRNA have not been delivered to BMECs using systemically administered nanoparticles. Given that in vitro nanoparticle screens have not identified nanoparticles with BMEC tropism, we developed a system to quantify how >100 different nanoparticles deliver siRNA in a sing...
20 CitationsSource
#1Cory D. Sago (Emory University)H-Index: 10
#2Melissa P. Lokugamage (Georgia Institute of Technology)H-Index: 8
Last. James E. Dahlman (Emory University)H-Index: 24
view all 17 authors...
Dysfunctional endothelium causes more disease than any other cell type. Systemically administered RNA delivery to nonliver tissues remains challenging, in large part because there is no high-throughput method to identify nanoparticles that deliver functional mRNA to cells in vivo. Here we report a system capable of simultaneously quantifying how >100 lipid nanoparticles (LNPs) deliver mRNA that is translated into functional protein. Using this system (named FIND), we measured how >250 LNPs deliv...
68 CitationsSource
#1Sam Chen (UBC: University of British Columbia)H-Index: 16
#2Josh Zaifman (UBC: University of British Columbia)H-Index: 6
Last. Pieter R. Cullis (UBC: University of British Columbia)H-Index: 117
view all 8 authors...
Abstract Lipid nanoparticles (LNPs) are playing a leading role in enabling clinical applications of gene therapies based on DNA or RNA polymers. One factor impeding clinical acceptance of LNP therapeutics is that LNP formulations of nucleic acid polymers can be immunostimulatory, necessitating co-administration of potent corticosteroid immunosuppressive agents. Here, we describe the development of hydrophobic prodrugs of a potent corticosteroid, dexamethasone, that can be readily incorporated in...
17 CitationsSource
#1Enamul Haque (Deakin University)H-Index: 26
#2Alister C. Ward (Deakin University)H-Index: 56
Nanoparticles are increasingly being developed for in vivo use, from targeted drug delivery to diagnostics, where they have enormous potential, while they are also being used for a variety of applications that can result in environmental exposure for humans. Understanding how specific nanoparticles interact with cells and cell systems is essential to gauge their safety with respect to either clinical or environmental exposure. Zebrafish is being increasingly employed as a model to evaluate nanop...
58 CitationsSource
#1Kalina Paunovska (Georgia Institute of Technology)H-Index: 5
#2Carmen J. Gil (Georgia Institute of Technology)H-Index: 6
Last. James E. Dahlman (Georgia Institute of Technology)H-Index: 24
view all 9 authors...
Lipid nanoparticles (LNPs) are formulated using unmodified cholesterol. However, cholesterol is naturally esterified and oxidized in vivo, and these cholesterol variants are differentially trafficked in vivo via lipoproteins including LDL and VLDL. We hypothesized that incorporating the same cholesterol variants into LNPs—which can be structurally similar to LDL and VLDL—would alter nanoparticle targeting in vivo. To test this hypothesis, we quantified how >100 LNPs made with six cholesterol var...
25 CitationsSource
#1David AdamsH-Index: 20
#1David H. AdamsH-Index: 206
Last. Ole B. Suhr (Umeå University)H-Index: 61
view all 36 authors...
BACKGROUND: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin.METHODS: In this phase 3 trial, we randomly assigned patients ...
875 CitationsSource
#1Staci SabnisH-Index: 6
Last. Kerry BenenatoH-Index: 5
view all 13 authors...
The success of mRNA-based therapies depends on the availability of a safe and efficient delivery vehicle. Lipid nanoparticles have been identified as a viable option. However, there are concerns whether an acceptable tolerability profile for chronic dosing can be achieved. The efficiency and tolerability of lipid nanoparticles has been attributed to the amino lipid. Therefore, we developed a new series of amino lipids that address this concern. Clear structure-activity relationships were develop...
123 CitationsSource
Cited By82
Abstract mRNA-based therapeutics have progressed significantly over the past decade and hold great potential to treat several diseases, including but not limited to cancer, infectious diseases, and genetic disorders. Many mRNA therapeutics are encapsulated in lipid nanoparticles (LNPs), which stabilize the mRNA and, following patient administration, transfect target cells to deliver the therapeutic mRNA. Developing reliable and robust in vitro bioassays is critical for expediting early screening...
#1Nicole Zoratto (Sapienza University of Rome)H-Index: 5
#2E. Montanari (ETH Zurich)
Last. Pietro Matricardi (Sapienza University of Rome)H-Index: 30
view all 7 authors...
Abstract Nowadays nanoparticles are increasingly investigated for the targeted and controlled delivery of therapeutics, as suggested by the high number of research articles (2400 in 2000 vs 8500 in 2020). Among them, almost 2% investigated nanogels in 2020. Nanogels or nanohydrogels (NGs) are nanoparticles formed by a swollen three-dimensional network of synthetic polymers or natural macromolecules such as polysaccharides. NGs represent a highly versatile nanocarrier, able to deliver a number of...
Abstract null null Novel nanocomposite system based on mesoporous silica nanoparticles (MSNs) noncovalently modified with hexadecyltriphenylphosphonium bromide (HTPPB) has been prepared, thoroughly characterized and used for encapsulation of model cargo Rhodamine B (RhB). The high encapsulation efficacy of this dye by HTPPB-modified mesoporous particles was demonstrated by spectrophotometry and thermography techniques. The bioavailability of MSN@HTPPB was testified. Cytotoxicity assay revealed t...
#1Rubén R. López (École de technologie supérieure)
#1Rubén R. López (École de technologie supérieure)H-Index: 2
Last. Catherine Mounier (UQAM: Université du Québec à Montréal)H-Index: 22
view all 12 authors...
Liposomes encapsulate different substances ranging from drugs to genes. Control over the average size and size distribution of these nanoparticles is vital for biomedical applications since these characteristics determine to a high degree where liposomes will accumulate in the human body. Micromixers enable the continuous flow synthesis of liposomes, improving size control and reproducibility. Recently, Dean flow dynamics-based micromixers, such as the periodic disturbance mixer (PDM), have been...
#1Marcelo Calderón (UPV/EHU: University of the Basque Country)H-Index: 32
#2Sarah Hedtrich (UBC: University of British Columbia)H-Index: 21
Despite exciting advances in gene editing, their clinical translation is still hampered by the lack of delivery systems that can encapsulate and deliver gene editing tools like CRISPR-Cas9 or prime editors to the target side. This is particularly challenging in human epithelia, such as the skin and the lung; the latter of which being a mucosal surface that is covered by a mucus layer. In this perspective, the design and biological assessment of delivery systems for gene editing tools like CRISPR...
#5Patrick C. Hillesheim (Ave Maria University)H-Index: 1
Gene therapy has been experiencing a breakthrough in recent years, targeting various specific cell groups in numerous therapeutic areas. However, most recent clinical studies maintain the use of traditional viral vector systems, which are challenging to manufacture cost-effectively at a commercial scale. Non-viral vectors have been a fast-paced research topic in gene delivery, such as polymers, lipids, inorganic particles, and combinations of different types. Although non-viral vectors are low i...
1 CitationsSource
#1Dan Wang (Peking Union Medical College)H-Index: 1
#2Xuelei Wang (Peking Union Medical College)H-Index: 1
Last. Bin Hong (Peking Union Medical College)H-Index: 21
view all 7 authors...
Abstract MicroRNA185 (miR185), an endogenous noncoding RNA with 23 nucleotides, is one of key posttranscriptional modulators of cholesterol metabolism in hepatic cells. The antisense inhibitor of miR185 (miR185i) could decrease cholesterol level in vivo, providing a promising agent for anti-atherosclerosis strategy. In this work, a novel LipomiR185i was constructed by thin film hydration method and post-PEGylation as DOPE: DOTAP: Chol: DSPE-PEG2000 at the molar ratio of 1:1:1:0.1 with a nitrogen...
Fabry disease (FD) is a monogenic X-linked lysosomal storage disorder caused by a deficiency in the lysosomal enzyme α-Galactosidase A (α-Gal A). It is a good candidate to be treated with gene therapy, in which moderately low levels of enzyme activity should be sufficient for clinical efficacy. In the present work we have evaluated the efficacy of a non-viral vector based on solid lipid nanoparticles (SLN) to increase α-Gal A activity in an FD mouse model after intravenous administration. The SL...
#1Lauren M Timmins (RU: Rutgers University)H-Index: 1
#2Alexandra Burr (RU: Rutgers University)H-Index: 1
Last. Biju Parekkadan (RU: Rutgers University)H-Index: 23
view all 11 authors...
When considering the development pathway for a genetically modified cell therapy product, it is critically important that the product is engineered consistent with its intended human use. For scientists looking to develop and commercialize a new technology, the decision to select a genetic modification method depends on several practical considerations. Whichever path is chosen, the developer must understand the key risks and potential mitigations of the cell engineering approach. The developer ...